Merus N.V. Files 8-K: Material Agreement & Financials
| Field | Detail |
|---|---|
| Company | Merus N.V. |
| Form Type | 8-K |
| Filed Date | Sep 29, 2025 |
| Risk Level | medium |
| Pages | 14 |
| Reading Time | 16 min |
| Key Dollar Amounts | $97.00, $240,000,000, $416,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, financials, filing
TL;DR
Merus N.V. signed a big deal and filed financials. Keep an eye on this.
AI Summary
On September 29, 2025, Merus N.V. filed an 8-K report detailing a material definitive agreement. The filing also included Regulation FD disclosures and financial statements/exhibits. Merus N.V. is incorporated in The Netherlands and its principal executive offices are located in Utrecht.
Why It Matters
This 8-K filing indicates a significant new agreement for Merus N.V., which could impact its future business operations and financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.
Key Players & Entities
- Merus N.V. (company) — Registrant
- September 29, 2025 (date) — Date of earliest event reported
- The Netherlands (location) — State or other jurisdiction of incorporation or organization
- Utrecht (location) — Address of principal executive offices
FAQ
What is the nature of the material definitive agreement filed by Merus N.V.?
The filing does not specify the details of the material definitive agreement, only that one has been entered into.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on September 29, 2025.
Where are Merus N.V.'s principal executive offices located?
Merus N.V.'s principal executive offices are located at Uppsalalaan 17, 3584 CT Utrecht, The Netherlands.
What other information is included in this 8-K filing besides the material definitive agreement?
The filing also includes Regulation FD Disclosure and Financial Statements and Exhibits.
What is Merus N.V.'s former company name and date of name change?
Merus N.V.'s former company name was Merus B.V., and the date of the name change was August 19, 2015.
Filing Stats: 4,079 words · 16 min read · ~14 pages · Grade level 17.9 · Accepted 2025-09-29 08:30:16
Key Financial Figures
- $97.00 — (the " Common Shares ") in exchange for $97.00 per Share, in cash (the " Offer Conside
- $240,000,000 — reed to pay Parent a termination fee of $240,000,000 under specified circumstances, includin
- $416,000,000 — to pay a regulatory termination fee of $416,000,000 to Merus if the Transaction Agreement i
Filing Documents
- d94293d8k.htm (8-K) — 70KB
- d94293dex21.htm (EX-2.1) — 603KB
- d94293dex991.htm (EX-99.1) — 45KB
- d94293dex992.htm (EX-99.2) — 38KB
- g94293dsp142a.jpg (GRAPHIC) — 6KB
- g94293g20p33.jpg (GRAPHIC) — 3KB
- 0001193125-25-221801.txt ( ) — 1061KB
- mrus-20250929.xsd (EX-101.SCH) — 3KB
- mrus-20250929_lab.xml (EX-101.LAB) — 17KB
- mrus-20250929_pre.xml (EX-101.PRE) — 11KB
- d94293d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 2.1* Transaction Agreement, dated as of September 29, 2025, by and among Genmab A/S, Genmab Holding II B.V. and Merus N.V. 99.1 Foundation Support Agreement, dated as of September 29, 2025, by and among G. Reijnen, R. van Leen and Merus N.V. 99.2 Joint Press Release, dated September 29, 2025 * Schedules and exhibits have been omitted pursuant to Item 601(b)(2) of Regulation S-K. Merus agrees to furnish supplementally a copy of any such schedule or exhibit to the U.S. Securities and Exchange Commission (the " SEC ") upon request. 5 Additional Information and Where to Find It The tender offer for Merus' outstanding common shares referenced herein has not commenced. This Current Report on Form 8-K (this " Current Report ") is not an offer to buy or a solicitation of an offer to sell any securities of Merus. The offer to buy common shares of Merus will only be made pursuant to a Tender Offer Statement on Schedule TO, including an offer to purchase, a letter of transmittal and other related materials that Parent intends to cause its acquisition subsidiary, Purchaser, to file with the SEC. In addition, Merus will file with the SEC a Solicitation/Recommendation Statement on Schedule 14D-9 with respect to the tender offer. Merus will also file with the SEC a proxy statement on Schedule 14A in connection with an extraordinary general meeting of shareholders of Merus, at which Merus shareholders will vote on certain proposed resolutions in connection with the proposed transactions, and will mail the definitive proxy statement and a proxy card to each shareholder entitled to vote at the extraordinary general meeting. Once filed, investors will be able to obtain a free copy of these materials and other documents filed by Parent, Purchaser and Merus with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, any such documents filed with
Forward-Looking Statements
Forward-Looking Statements This Current Report contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this Current Report that are not a description of historical facts are forward-looking statements. Words or phrases such as "believe," "may," "could," "will," "estimate," "continue," "anticipate," "intend," "seek," "plan," "expect," "should," "would" or similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these words. The forward-looking statements are based on current beliefs and expectations and include, but are not limited to, statements regarding the planned completion of the transactions contemplated by the Transaction Agreement and related timing, as well as the potential effects of the proposed transactions on Merus. Risks and uncertainties that could cause results to differ materially from expectations include without limitation: uncertainties as to the timing and completion of the tender offer and the proposed transactions; uncertainties as to the percentage of Merus shareholders tendering their shares in the tender offer and as to the percentage of Merus shareholders voting in favor of the matters relating to the proposed transactions at the extraordinary general meeting; the possibility that competing offers will be made; the possibility that various closing conditions for the tender offer or the proposed transactions may not be satisfied or waived, including the failure to receive any required regulatory approvals from any applicable governmental entities (or any conditions, limitations or restrictions placed on such approvals); the effects of disruption caused by the proposed transactions making it more difficult to maintain relationships with employees, collaborators, vendors and other business partners; risks related to diverting management's attention from Merus's ongoing business operations;
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MERUS N.V. /s/ Sven (Bill) Ante Lundberg Date: September 29, 2025 Name: Sven (Bill) Ante Lundberg, M.D. Title: President and Chief Executive Officer